Yiling Pharmaceuticals: Letermovir API received approval for market application.

Yiling Pharmaceuticals announced that the "Letrozole" chemical raw material drug application submitted by its wholly-owned subsidiary Wanyang Hengshui Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration. Letrozole is an efficient and selective non-steroidal aromatase inhibitor used in the treatment of breast cancer. The global market size for breast cancer drugs is expected to reach $37.6 billion by 2025 and $45 to $55 billion by 2030. The incidence of breast cancer in China is increasing annually, and the demand for raw materials in the market is expected to continue to grow. The company has invested approximately 4.7 million yuan in the research and development of Letrozole raw materials. This approval enriches the company's product line and helps to expand its business scope, but it is not expected to have a significant impact on the performance at present.